Acquisition Opportunity Innovis Pharma is recently acquired by PharmaPath, creating an integrated Greek pharmaceutical group with strong R&D, manufacturing capabilities, and commercial reach. This signals potential cross-sell opportunities across the combined portfolio, enhanced distribution, and unified procurement for future product launches.

Growth Potential With a revenue range between one and ten million dollars and a growing portfolio that includes generics, specialty brands, medical devices, and dietary supplements, there are multiple entry points for expanding access, including contract manufacturing, private label deals, and strategic partnerships.

Digital & Compliance The tech stack includes AWS, Cloudflare, OneTrust, Salesforce, SAP, and Microsoft 365, indicating mature IT and compliance capabilities. This supports enterprise sales motions, scalable e-commerce or CRM-driven partnerships, and robust data governance for joint ventures.

Market Position Based in Athens and serving the Greek market with patient-centric solutions across major therapeutic areas, Innovis Pharma presents an attractive regional platform for accelerated regional expansion, licensing opportunities, and collaborative R&D commercialization within Southern Europe.

Operational Scale The combination of manufacturing capabilities, a diversified product mix, and recent enterprise-level IT adoption suggests readiness for large-scale supply agreements, long-term distribution deals, and accelerated onboarding of new products to support PharmaPath’s integrated group strategy.